Mitomycine Accord (Mitomycin)

Mitomycin is a bioreductive alkylating agent. Inside low‑oxygen tumor cells it is reduced to reactive species that cross‑link DNA strands, preventing DNA synthesis and triggering programmed cell death of rapidly dividing cancer cells.

The dose of Mitomycine Accord is determined by the prescribing oncologist based on the patient’s clinical condition, tumor stage, and route of administration. Only a qualified healthcare professional should set the exact regimen.

Mitomycin is classified as contraindicated in pregnancy because it can cross the placenta and cause fetal harm. Breastfeeding is also not recommended, as the drug may be excreted in milk and affect the infant. Consultation with a specialist is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with agents such as bacillus Calmette‑Guérin (BCG) or other intravesical chemotherapeutics, mitomycin offers a distinct DNA‑cross‑linking mechanism. It is often chosen for patients who cannot tolerate BCG or when a non‑live therapy is preferred, though efficacy and safety profiles differ and must be evaluated individually.

Store at controlled room temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from light, moisture, and extreme temperature fluctuations. Do not freeze. Follow aseptic techniques when preparing for intravenous or intravesical administration.

The product is supplied as a sterile solution for injection. It can be given intravenously for systemic exposure or instilled directly into the bladder (intravesical) using a catheter, following the dosing schedule prescribed by the treating oncologist.

The most serious risks include severe bone‑marrow suppression leading to anemia, neutropenia, or thrombocytopenia; life‑threatening infections; pulmonary toxicity such as interstitial pneumonitis; and rare but severe hemolytic‑uremic syndrome. Prompt monitoring and supportive care are essential.

Patients with active uncontrolled infections, severe pulmonary disease, significant renal impairment, or those receiving other myelosuppressive chemotherapy should avoid Mitomycine Accord. It is also contraindicated in pregnant women and is not recommended for breastfeeding mothers.